Guangdong Hybribio Biotech (SHE:300639) subsidiary Guangzhou Kaipu Pharmaceutical Technology will conduct clinical trials on chloroquine phosphate gel after receiving approval from China's National Medical Products Administration, a Saturday filing on the Shenzhen Stock Exchange said.
The drug will be tested as a treatment for patients with human papillomavirus.
Price (RMB): ¥5.06, Change: ¥+0.020, Percent Change: +0.40%
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。